

**Oncology Today with Dr Neil Love: EGFR Mutation-Positive Non-Small Cell Lung Cancer Edition (Video Presentation)****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following disease-free survival outcomes was reported from the Phase III ADAURA trial evaluating osimertinib as adjuvant therapy after complete tumor resection for patients with Stage IB to IIIA non-small cell lung cancer (NSCLC) with EGFR mutations?**
  - Statistically significant improvement over placebo for patients with Stage IB to IIIA disease
  - Statistically significant improvement over placebo for patients with Stage II and IIIA but not Stage IB disease
  - No statistically significant improvement over placebo in any subgroup
- 2. The investigational agent mobocertinib (TAK-788) has shown promising activity in the treatment of metastatic NSCLC with which type of EGFR mutation?**
  - Exon 19 deletion
  - Exon 20 insertion mutation
  - Exon 21 mutation
- 3. Which of the following drug types best describes the mechanism of action of the novel agent patritumab deruxtecan (U3-1402)?**
  - EGFR tyrosine kinase inhibitor
  - HER3-directed antibody-drug conjugate
  - MET inhibitor
- 4. Results of the Phase III FLAURA trial comparing osimertinib to gefitinib or erlotinib for patients with untreated advanced NSCLC with EGFR mutations reported which outcome with osimertinib?**
  - Improvement in progression-free survival (PFS) only
  - Improvement in overall survival (OS) only
  - Improvement in both PFS and OS